Literature DB >> 16321888

Eosinophil activation in Wegener's granulomatosis: a harbinger of disease progression?

Pitipol Choopong1, Nadia Khan, Virender S Sangwan, Panayotis Zafirakis, Charalampos Livir Rallatos, Blanca Rojas, Stefanos Baltatzis, C Stephen Foster.   

Abstract

PURPOSE: To investigate the relation between eosinophil activation in tissue from patients with an active, limited form of Wegener's granulomatosis (WG) affecting the eye and subsequent systemic disease activity.
METHODS: Analysis of ocular specimens obtained from 10 patients was performed. Sections were probed with antibodies to assess the presence of major basic protein (MBP) and eosinophil cationic protein (ECP).
RESULTS: Four of the 10 specimens demonstrated the presence of MBP and ECP. WG progressed to the complete form in two of these patients, who received no or inadequate treatment. The other two, treated with cyclophosphamide for one year, did not progress to the complete form of WG during observation after therapy.
CONCLUSIONS: Activated eosinophils in sclera or conjunctiva of patients with ocular limited WG may predict progression to complete WG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16321888     DOI: 10.1080/09273940591004250

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  4 in total

1.  Histopathological features predictive of a clinical diagnosis of ophthalmic granulomatosis with polyangiitis (GPA).

Authors:  Hazlita Isa; Sue Lightman; Philip J Luthert; Geoffrey E Rose; David H Verity; Simon R J Taylor
Journal:  Int J Clin Exp Pathol       Date:  2012-09-05

Review 2.  Eosinophils in vasculitis: characteristics and roles in pathogenesis.

Authors:  Paneez Khoury; Peter C Grayson; Amy D Klion
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 3.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.834

4.  [Vasculitides and eosinophilic pulmonary diseases].

Authors:  C Kroegel; M Foerster; S Quickert; H Slevogt; T Neumann
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.